A preclinical drug that inhibits the kinase enzyme Cdk5 may have the potential to treat depression, brain injuries, and disorders associated with cognitive impairment.
Researchers have identified six predictors that may help determine the correct amount of lithium to treat a patient with bipolar disorder.
Fetal exposure to antidepressants or antiepileptic medications may affect the development of newborn brain networks.
Disulfiram, a drug commonly prescribed to treat chronic alcohol addiction, was shown to reduce anxiety levels in rodent models. The drug inhibits FROUNT protein and chemokine signaling pathways under its influence, suppressing overall glutamate transmission in the brain. This, in turn, helps reduce overall activity. The findings may signal a new way to treat anxiety in humans.
Mouse study reveals synaptic loss associated with a daily sleep-inducing dose of diazepam for several weeks leads to cognitive impairments. However, the effect was reversible after discontinuing benzodiazepine use.
A growing body of evidence suggests psychedelics including psilocybin and LSD show promise in providing lasting relief from symptoms for those suffering some mental health disorders. Researchers found DOI, a similar drug to LSD, reduced negative behavioral responses following fear triggers in mouse models of anxiety.
Mirtazapine, an antidepressant commonly prescribed to treat dementia-associated agitation, is no more effective than a placebo and may increase mortality risks, researchers report.
Moment-to-moment fluctuations in brain activity over a three-minute period can reliably predict how receptive a person with social anxiety will be to cognitive behavioral therapy.
Trihexyphenidyl, an anticholinergic medication commonly prescribed for Parkinson's symptoms, appears to alleviate negative memory flashbacks and nightmares experienced by those with PTSD.